EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital
Increase
Marinomed Biotech AG resolves second capital increase excluding statutory
subscription rights by issuing 83,750 no-par value bearer shares at an
issue price of EUR 8 per share
05-Dec-2024 / 14:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the
“Company”) announces that the Management Board has resolved today to
increase the Company's share capital again by EUR 83,750 to EUR 1,778,333
by issuing 83,750 new no-par value bearer shares against cash
contributions (the “Second Capital Increase”). The new shares will be
issued from the authorized capital 2024 under exclusion of statutory
subscription rights of existing shareholders. A report on the intended
exclusion of the subscription rights of existing shareholders (the
“Report”) was published on the Company's website from November 28, 2024
onwards, and on the electronic announcement and information platform of
the Federal Government of Austria ("EVI") on November 28, 2024. The issue
price per new share is EUR 8 so that the total issue price amounts to EUR
670,000. The required Supervisory Board resolution for the Second Capital
Increase under exclusion of statutory subscription rights can be passed no
earlier than two weeks after publication of the Report. The Company had
already provided information on a possible second capital increase in ad
hoc announcements of September 2, September 15, September 18 and November
27, 2024.
All 83,750 new shares have been subscribed by a total of nine individually
approached investors at these issue terms and conditions.
+++ End of ad-hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
05-Dec-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2045241
End of Announcement EQS News Service
2045241 05-Dec-2024 CET/CEST
